Metastatic prostate cancer can progress in different ways. In some men the disease advances rapidly, while other men have ...

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

"PARP inhibitors have been a mainstay in the treatment of metastatic castration-resistant prostate cancer for patients with ...

The FDA approval is based on safety and efficacy demonstrated in the phase 3 ARANOTE trial, which evaluated darolutamide — ...

The viral immunotherapy delivers a replication-defective herpes simplex virus thymidine kinase gene and was administered in ...

Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and ...

The approval is based on results from the phase 3 ARANOTE trial, which showed Nubeqa, when combined with androgen deprivation ...

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...

The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, phase 3 ARANOTE trial.

Approval was based on results from the Phase III ARANOTE trial, in which Nubeqa demonstrated a 46% reduction in the risk of ...